LivaNova PLC (LIVN)
NEUTRALFondamental
66
Prix
$79.49
Capitalisation boursière
$4.31B
Partie 1 · Ce que vaut l'entreprise
Vue d'ensemble
LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories, as well as services related products. The Neuromodulation segment offers VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals; and devices that deliver neuromodulation therapy for treating drug-resistant epilepsy and depression. This segment also includes the development and clinical testing of aura6000 system for treating obstructive sleep apnea. It serves perfusionists, neurologists, neurosurgeons, hospitals, other healthcare professionals and medical institutions, and healthcare providers. The company sells its medical devices through direct sales representatives, agents, and independent distributors in the United States, the United Kingdom, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland, Denmark, and internationally. LivaNova PLC was incorporated in 2015 and is headquartered in Gloucester, the United Kingdom.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Bilan & Liquidités
Chiffre d'affaires
$1.47B
12 derniers mois (au 30/06/2026)
Résultat net
$189M
12 derniers mois (au 30/06/2026)
Flux de trésorerie libre
$173M
Capitaux propres totaux
$1.20B
Passif total
$1.41B
Ratio de liquidité général
1.45
Couverture des intérêts
5.43
Dette/EBITDA
1.30
Bénéfice par action
Chiffre d'affaires & Résultat net
Flux de trésorerie libre
Décomposition du résultat
État historique
Marges dans le temps
La dette dans le temps
Le poids de la dette
Grille de la croissance
Croissance — Chiffre d'affaires
Estimation de la juste valeur
Juste valeur
$68.03
Prix actuel
$79.49
Marge de sécurité
-16.8%
Fourchette de juste valeur
$50.54 - $85.52
Méthodes d'estimation
Indicateurs de valorisation
Ratio P/E
23.09
ROE
-20.2%
Ratio P/B
3.25
P/FCF
29.07
Marge brute
68.1%
ROIC
7.7%
Radar de rentabilité
Value Creation (Economic Moat)
ROIC
7.7%
WACC
9.4%
ROIC − WACC
-1.8 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Critères d'analyse fondamentale
Réussi (18)
- Price CAGR 5.76%
- ROIC 7.7%
- Gross Margin 68.1%
- P/FCF 29.07
- Debt/Equity ratio
- Operating Margin 12.7%
- Positive Free Cash Flow
- Current Ratio
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- ROE 15.4%
- Revenue Growth 5Y 8.2%
- Analyst Consensus 81% Buy
- Earnings Surprise avg 10.3%
- Earnings Quality (OCF/NI) 1.32
- Share Dilution -0.0%
- Net Margin Trend 12.8% vs -16.1%
Échoué (7)
- EPS shows upward trend
- P/B Ratio 3.25
- CapEx intensity
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- Piotroski F-Score 4/9
Indisponible (2)
- Dividend Payout NaN%
- PEG Ratio (need PE > 0 and growth > 0)
Score F de Piotroski
Signaux mixtes : certains domaines nécessitent attention
Qualité des bénéfices
Qualité élevée : bénéfices soutenus par la trésorerie
Dilution du capital
Rachat d'actions. Favorable aux actionnaires
Gouvernance
Équipe dirigeante
| Nom | Titre | Âge |
|---|---|---|
| Mr. Vladimir A. Makatsaria | CEO & Director | 52 |
| Mr. Alex Shvartsburg C.M.A. | Chief Financial Officer | 55 |
| Ms. Natalia Sergeyevna Kozmina | Chief Human Resources Officer | 54 |
| Mr. Ahmet Tezel Ph.D. | Chief Innovation Officer | 50 |
| Ms. Lindsey Little | VP & Chief Accounting Officer | - |
| Briana Gotlin | Vice President of Investor Relations | - |
| Ms. Sarah K. Mohr | VP of Legal & Company Secretary | - |
| Deanna Wilke | Vice President of Corporate Communications | - |
| Mr. Philip Kowalczyk | Chief Strategy & Corporate Development Officer | - |
| Mr. Paul R. Buckman | President of Advanced Circulatory Support & GM of Transcatheter Mitral Valve Replacement | 69 |
Risque d'audit
9
Risque du conseil
3
Risque de rémunération
2
Risque droits des actionnaires
2
Partie 2 · Le prix et le moment d'entrer
Cette partie ne dit pas si l'entreprise vaut la peine : elle aide à choisir quand l'acheter, une fois que les fondamentaux vous ont convaincu. À l'intérieur : analyse technique, potentiel, baisses historiques, exposition gamma.
Latest News
Recent headlines for LIVN, sourced from Markets Gazette.
- 2/25/2026NEUTRALLivaNova (LIVN) Q4 2025 Earnings Call Transcript
The transcript of LivaNova PLC's Q4 2025 earnings conference call is now available, providing investors with a critical opportunity to delve into the company's financial performance and future outlook. While the specific content has not been disclosed, analysts and shareholders will be scrutinizing management's statements regarding revenues, profit margins, product pipeline, and guidance for the current fiscal year. This data is essential for assessing LivaNova's operational health and anticipating potential stock movements, thereby influencing both short-term and long-term investment strategies.
via Markets Gazette